title: Response to letter regarding article, “histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid”.
authors.forename: Lan
authors.initials: L
authors.lastname: Zhao
authors.forename: Chien-Nien
authors.initials: CN
authors.lastname: Chen
authors.forename: Nabil
authors.initials: N
authors.lastname: Hajji
authors.forename: Eduardo
authors.initials: E
authors.lastname: Oliver
authors.forename: Emanuele
authors.initials: E
authors.lastname: Cotroneo
authors.forename: John
authors.initials: J
authors.lastname: Wharton
authors.forename: Martin R
authors.initials: MR
authors.lastname: Wilkins
authors.forename: Daren
authors.initials: D
authors.lastname: Wang
authors.forename: Min
authors.initials: M
authors.lastname: Li
authors.forename: Kurt R
authors.initials: KR
authors.lastname: Stenmark
authors.forename: Timothy A
authors.initials: TA
authors.lastname: McKinsey
authors.forename: Peter
authors.initials: P
authors.lastname: Buttrick
mesh_terms: D000818:Animals; D006655:Histone Deacetylases / Q000187:drug effects*; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology* / Q000627:therapeutic use*; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D008297:Male; D014635:Valproic Acid / Q000494:pharmacology* / Q000627:therapeutic use*
chemical_list: D006877:Hydroxamic Acids; D014635:Valproic Acid; D006655:Histone Deacetylases